Navigation Links
BioDrain Streamway® System Receives Positive Evaluations on Two Additional Units
Date:6/27/2011

MINNEAPOLIS, June 27, 2011 /PRNewswire/ -- BioDrain Medical, Inc. (OTCBB: BIOR, OTCQB: BIOR), producer of the FDA cleared Streamway® System for automated surgical fluid disposal, today announced that it has placed two additional units and that new evaluations are underway at surgical facilities in Minnesota.  The Streamway System has received positive reviews and feedback from surgical personnel at both sites.

Healthcare personnel trained in the use of the Streamway System were especially pleased with its ease of use, the efficiency of the automated disposal of surgical fluids, and the minimal risk of exposure to hazardous waste.

Kevin Davidson, CEO of BioDrain, declared, "These evaluations were conducted at two hospitals as part of our normal sales process and contribute to BioDrain's development of its market position. We are very pleased that surgical personnel in these facilities are finding the Streamway System to be a highly efficient and cost-effective means to automatically dispose of surgical waste fluid. This breakthrough system has now been used in over 300 live operations as part of our product launch phase. We are delighted with the enthusiastic response and look forward to further opportunities at these sites as well as other surgical facilities."

About BioDrain Medical, Inc.

BioDrain Medical, Inc. has a fully automated, patented, FDA cleared, surgical fluid disposal system that virtually eliminates operating room workers' exposure to blood, irrigation fluid and the related germs, viruses and diseases that are potentially found in the surgical environment. Today's manual surgical fluid handling methods of hand-carrying filled surgical fluid canisters and emptying these canisters is an exposure risk and an antiquated approach to the handling of surgical fluid waste. BioDrain's Streamway system fully automates the collection, measurement and disposal of surgical fluids resulting in: 1) reducing overhead costs to hospitals and surgical centers, 2) improving the Occupational State and Health Association (OSHA) and other regulatory compliance, and 3) improving the efficiency of the operating room (and thereby making surgeries more profitable).

BioDrain's Streamway System is eco-friendly as it contributes to cleaning up the environment. Currently, approximately 50 million bloody, potentially disease infected, canisters go to landfills annually in the United States. These tainted canisters can remain in landfills for years to come. With the installation of BioDrain's Streamway system, the number of canisters can be significantly reduced. BioDrain Medical, Inc. makes the operating room and our environment safer, cleaner, and better. BioDrain products are currently being represented by independent professional sales representatives that cater to the needs of hospitals and ambulatory surgical centers across the country.

Forward-looking Statements:

Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the company's ability to implement its long range business plan for various applications of its technology; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the company's reports filed with the Securities and Exchange Commission. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position. See the Company's most recent Quarterly Report on Form 10-Q and related 8-K filings.

Investor Relations Contact:
Stanley Wunderlich
Consulting for Strategic Growth 1 Ltd.
Tel: 800-625-2236 ext. 7770
Email: info@cfsg1.com


'/>"/>
SOURCE BioDrain Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioDrain Medical, Inc. Reports Results of Annual Meeting
2. BioDrain Medical, Inc. Retains EKN Financial Services as Its Exclusive Financial Advisor and Placement Agent
3. BioDrain Medical, Inc. Completes Installation of Its Streamway™ Automated Surgical Fluid Disposal System in Minnesota Hospital
4. BioDrain Medical, Inc. Retains CFSG1 as Its U.S. Investor Relations Firm
5. BioDrain Medical, Inc. Is Eligible for Trading on the OTCBB, Notice of Allowance on Canadian Patent Application
6. SweetSpot Diabetes Care, Inc. Registers SweetSpot Data Transfer Service as a Medical Device Data System (MDDS) With FDA
7. PharmacoFore, Inc. Announces Positive Results from a Phase I Clinical Study of Its Hydromorphone Bio-Activated Molecular Delivery™ System, and Upcoming Presentation at the 2011 BIO Business Forum During the Annual BIO International Convention in Was
8. Luminex Corporation Named Most Innovative Company of the Year and Receives Business Innovation of the Year Award for MAGPIX® System
9. Kinetics Foundation and National Parkinson Foundation (NPF) Announce their Partnership to Evaluate Objective Parkinsons Disease Measurement System
10. National Association of Public Hospitals and Health Systems to Galvanize Member Relationships on Within3
11. Still River Systems Sign Patent License Agreement With the Massachusetts Institute of Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... and Company (NYSE: LLY ) today announced that the ... patent would not presently be infringed by Actavis marketing pemetrexed ... Italy and Spain ... --> --> In ... Lilly,s patent would be indirectly infringed by Actavis marketing certain ...
(Date:2/12/2016)... , Feb. 12, 2016  Apellis Pharmaceuticals, ... a $47.1 million Series D preferred stock ... Management, Hillhouse Capital Group and venBio Global ... Investments, AJU IB Investment, and Epidarex Capital. The ... to further advance clinical trials in the ...
(Date:2/11/2016)... 11, 2016 The primary goal of this ... patterns on the usage of liquid biopsy. Key information ... - Timeframe of liquid biopsy adoption amidst future ... Evs—by organization type - Sample inflow to conduct liquid ... stool, serum, and so on. - Correlation analysis of ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... Basketball is a game for everyone, not ... Peety PoppersTM series, sign language translation is featured in the top right of the ... Peety PoppersTM lessons has a sign language translator to teach kids the game and ...
(Date:2/11/2016)... ... February 12, 2016 , ... Fitbody Personal Training offers outdoor training ... exciting way to get fit and healthy. Located in Phoenixville, PA, the classes are ... class designed for horseback riders who want to lose weight and tone up. This ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... participated in the American Osteopathic Association’s (AOA) Match Program Tuesday, February 9, taking ... Program places students into osteopathic graduate medical education positions across the country. Of ...
(Date:2/11/2016)... ... February 12, 2016 , ... The Journal of ... from 0.416 in 2013. The SJR uses data taken from the Scopus database (Elsevier ... the number of citations received by the journal over a three year period and ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... diabetes has been gearing up for their simultaneous grand openings in March. All ... right now that you’re probably wondering, is reversing diabetes possible? According to this ...
Breaking Medicine News(10 mins):